Speakers

Government Speakers

Allan Medina

Chief, Health Care Fraud Unit
Criminal Division, Fraud Section, Department of Justice

Prosecutorial Perspectives on Recent Settlements, OIG’s Guidance, and Enforcement Priorities for 2021

March 18, 2021 • 1:45 pm

Jolie Apicella

Chief, Health Care Fraud Unit
United States Attorney’s Office, Eastern District of New York

Prosecutorial Perspectives on Recent Settlements, OIG’s Guidance, and Enforcement Priorities for 2021

March 18, 2021 • 1:45 pm

Lee M. Cortes, Jr.

Chief, Health Care Fraud Unit
United States Attorney’s Office, District of New Jersey

Prosecutorial Perspectives on Recent Settlements, OIG’s Guidance, and Enforcement Priorities for 2021

March 18, 2021 • 1:45 pm

Amanda Masselam Strachan

Chief, Health Care Fraud Unit
United States Attorney’s Office, District of Massachusetts

Prosecutorial Perspectives on Recent Settlements, OIG’s Guidance, and Enforcement Priorities for 2021

March 18, 2021 • 1:45 pm

2021 Conference Co-chairs

Katherine DeKam

Chief Compliance Officer
Acumed

Practical Analysis of a Game Changer: Interpreting the November 2020 Special Fraud Alert on Speaker Programs

March 18, 2021 • 1:00 pm

Seth H. Lundy

Partner
King & Spalding LLP

Practical Analysis of a Game Changer: Interpreting the November 2020 Special Fraud Alert on Speaker Programs

March 18, 2021 • 1:00 pm

Speakers

Sean C. Cenawood

Partner
Dentons

The Real-Life Lessons from the Novartis, Gilead, and Biogen Settlements: Key Liability Risks Relating to Speaker and Patient Assistance Programs

March 18, 2021 • 2:45 pm

Stephen Chien

Global Compliance Lead, Senior Associate General Counsel
Gilead Sciences

Perspectives on Staying Compliant in the Context of the Pandemic, Managing Interactions with HCPs, and Keeping up with Evolving Regulatory Requirements

March 18, 2021 • 4:15 pm

Richard S. Liner

Senior Assistant General Counsel
Bayer Pharmaceuticals

Perspectives on Staying Compliant in the Context of the Pandemic, Managing Interactions with HCPs, and Keeping up with Evolving Regulatory Requirements

March 18, 2021 • 4:15 pm

Michael K. Loucks

Partner
Skadden, Arps, Slate, Meagher & Flom LLP

What the Newest AKS Safe Harbors Mean for Pharmaceutical and Medical Device Manufacturers

March 18, 2021 • 5:15 pm

Katie McDermott

Partner
Morgan, Lewis & Bockius LLP

Perspectives on Staying Compliant in the Context of the Pandemic, Managing Interactions with HCPs, and Keeping up with Evolving Regulatory Requirements

March 18, 2021 • 4:15 pm

Rebecca L. Orttel

Chief Counsel, U.S. Market and Global Health Law COE; Chief of Staff, Americas Region
Medtronic

Perspectives on Staying Compliant in the Context of the Pandemic, Managing Interactions with HCPs, and Keeping up with Evolving Regulatory Requirements

March 18, 2021 • 4:15 pm

David H. Resnicoff

Partner
Riley Safer Holmes & Cancila LLP

Prosecutorial Perspectives on Recent Settlements, OIG’s Guidance, and Enforcement Priorities for 2021

March 18, 2021 • 1:45 pm

William A. Sarraille

Partner
Sidley Austin

The Real-Life Lessons from the Novartis, Gilead, and Biogen Settlements: Key Liability Risks Relating to Speaker and Patient Assistance Programs

March 18, 2021 • 2:45 pm

James Stansel

Executive Vice President & General Counsel
PhRMA

What the Newest AKS Safe Harbors Mean for Pharmaceutical and Medical Device Manufacturers

March 18, 2021 • 5:15 pm

Julie Ritchie Wagner

Senior Assistant General Counsel
PhRMA

What the Newest AKS Safe Harbors Mean for Pharmaceutical and Medical Device Manufacturers

March 18, 2021 • 5:15 pm